Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-25
2008-08-26
Wilson, James (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S466000
Reexamination Certificate
active
07417040
ABSTRACT:
Disclosed are fused tricyclic compounds of the following formula I,or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof. The disclosed compounds are useful as inhibitors of 17β-hydroxysteriod dehydrogenase 3 (17βHSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer and pharmaceutical compositions comprising such compounds.
REFERENCES:
patent: 3336293 (1967-08-01), Cusic et al.
patent: 3336303 (1967-08-01), Coyne et al.
patent: 3367930 (1968-02-01), Schmutz et al.
patent: 3676432 (1972-07-01), Helsley
patent: 3714148 (1973-01-01), Okamoto et al.
patent: 4209523 (1980-06-01), Lafon
patent: 4888335 (1989-12-01), Mohrbacher et al.
patent: 5112867 (1992-05-01), Kinoshita et al.
patent: 5171745 (1992-12-01), De Noble et al.
patent: 5296493 (1994-03-01), Moldt et al.
patent: 5348965 (1994-09-01), Andersen et al.
patent: 5514505 (1996-05-01), Limburg et al.
patent: 5598551 (1997-01-01), Barajas et al.
patent: 5599815 (1997-02-01), Fukuda et al.
patent: 5998613 (1999-12-01), Falch et al.
patent: 6025355 (2000-02-01), Reddy et al.
patent: 6114381 (2000-09-01), Pitzele et al.
patent: 6235730 (2001-05-01), Sato et al.
patent: 6281212 (2001-08-01), Schwender et al.
patent: 6323206 (2001-11-01), Schwender et al.
patent: 6353018 (2002-03-01), Jeppesen et al.
patent: 6534496 (2003-03-01), Ishihara et al.
patent: 6543496 (2003-04-01), Woodruff
patent: 6960474 (2005-11-01), Salvati et al.
patent: 2004/0176324 (2004-09-01), Salvati et al.
patent: 2005/0191707 (2005-09-01), Lorenzi et al.
patent: 2005/0192310 (2005-09-01), Gavai et al.
patent: 06234753 (1994-08-01), None
patent: 07033744 (1995-02-01), None
patent: 2001-247573 (2001-09-01), None
patent: WO 9212133 (1992-07-01), None
patent: WO 9315052 (1993-08-01), None
patent: WO 9315073 (1993-08-01), None
patent: WO 9322302 (1993-11-01), None
patent: WO 9413291 (1994-06-01), None
patent: WO 9509634 (1995-04-01), None
patent: WO 9509858 (1995-04-01), None
patent: WO 9518615 (1995-07-01), None
patent: WO 9605185 (1996-02-01), None
patent: WO 9631500 (1996-10-01), None
patent: WO 9722342 (1997-06-01), None
patent: WO 9730054 (1997-08-01), None
patent: WO 9909991 (1999-03-01), None
patent: WO 9920599 (1999-04-01), None
patent: WO 9946279 (1999-09-01), None
patent: WO 0018721 (2000-04-01), None
patent: WO 0020398 (2000-04-01), None
patent: WO 0032193 (2000-06-01), None
patent: WO 0072833 (2000-12-01), None
patent: WO 0200653 (2002-01-01), None
patent: WO 03022835 (2003-03-01), None
patent: WO 2005/094816 (2005-10-01), None
Fink et al. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1532-1536.
Sax et al. Hawley's Condensed Chemical Dictionary, Eleventh Edition, 1987, pp. 1079-1080.
Patani and LaVoie. Chemical Reviews, 1996, 96, 3147-3176.
Giuseppe et al. Expert Opinion on Therapeutic Patents, 1997, 7(4), 307-323.
Vippagunta et a. Advanced Drug Delivery Reviews, 2001, 48, 3-26.
Kametani et al. Journal of the Chemical Society (C), 1971, pp. 1800-1803.
Gheiler, E. L., et al., Current concepts in androgen deprivation therapy—is there a “best” endocrine treatment?, World J. Urology., vol. 18, pp. 190-193, (2000).
Inano, H., et al., “Testicular 17β-Hydroxysteroid Dehydrogenase: Molecular Properties and Reaction Mechanism”, Steroids, vol. 48(1-2), pp. 1-26, (1986).
Jalsovszky, I., et al., “The extent of transannular sulfur-nitrogen interactions in stereoisomeric 1,5-thiazocine derivatives: a semiempirical MO study”, Journal of Molecular Structure, vol. 365, pp. 93-102, (1996).
Jalsovszky, I., et al., “Transannular sulfur-nitrogen interactions in stereoisomeric 1,5-thiazocine derivatives: An ab initio MO study”, Journal of Molecular Structure, vol. 418, pp. 155-163, (1997).
Kisel, V. M., “Synthesis and Properties of Novel Dibenz[b,f]Azocines”, Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 1, pp. 92-95, (1991).
Kuti, M., et al., “Transannular sulfur-nitrogen interaction in 1,5-thiazocine derivatives: an X-ray study”, Journal of Molecular Structure, vol. 382, pp. 1-11, (1996).
Labrie, F., “At the Cutting Edge Intracrinology”, Molecular and Cellular Endocrinology, vol. 78, pp. C113-C118, (1991).
Labrie, F. et al. “History of LHRH agonist and combination therapy in prostate cancer”, Endocrine-Related Cancer, vol. 3, pp. 243-278, (1996).
Liu, X., et al., “Androgens Regulate Proliferation of Human Prostate Cancer Cells in Culture by Increasing Transforming Growth Factor-α Receptor”, Journal of Clinical Endocrinology and Metabolism, vol. 77(6), pp. 1472-1478.
Luu-The, V., “Characteristics of Human Types 1,2 and 3 17β-Hydroxysteroid Dehydrogenase Activities: Oxidation/Reduction and Inhibition”, J. Steroid Biochem. Molec. Biol., vol. 55(5/6), pp. 581-587, (1995).
Maltais, R., et al., “Synthesis and Optimization of a New Family of Type 3 17β-Hydroxysteroid Dehydrogenase Inhibitors by Parallel Liquid-Phase Chemistry”, J. Med. Chem., vol. 45, pp. 640-653, (2002).
Pittaway, D. E., “Inhibition of Testosterone Synthesis in the Canine Testis in Vitro”, Contraception, vol. 27(4), pp. 431-436, (1983).
Simard, J., et al., “Comparison of in Vitro Effects of the Pure Antiandrogens OH-Flutamide, Casodex, and Nilutamide on Androgen-Sensitive Parameters”, Urology, vol. 49(4), pp. 580-589, (1997).
Van Weerden, W.M., “Effects of Low Testosterone Levels and of Adrenal Androgens on Growth of Prostate Tumor Models in Nude Mice”, J. Steroid Biochem. Molec. Biol., vol. 6, pp. 903-907, (1990).
Kambe, et al., “Intramolecular 1,3-Dipolar Cycloaddition Strategy for Enantioselective Synthesis of FR-900482 Analogues”, Organic Letters, vol. 3(16), pp. 2575-2578, (2001).
Cooper et al., Cyclic Amidines. Part IV. 5:6:22:23-Tetrahydro-5:11-endomethylenephenhomazines and Troger's Base, Journal of the Chemical Society, Abstracts, pp. 991-994, (1955).
PCT International Search Report (PCT/US05/06548) mailed Dec. 7, 2005.
PCT International Search Report (PCT/US05/06549) mailed Dec. 13, 2005.
U.S. Appl. No. 11/255,484, filed Oct. 21, 2005, Bristol Myers Squibb Co.
Fink Brian E.
Gavai Ashvinikumar V.
Han Wen-Ching
Misra Raj N.
Norris Derek J.
Bristol--Myers Squibb Company
Greenblatt Gary D.
Jarrell Noble
Wilson James
LandOfFree
Fused tricyclic compounds as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused tricyclic compounds as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused tricyclic compounds as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019700